Novel recombinant parapoxvirus vectors induce protective humoral and cellular immunity against lethal herpesvirus challenge infection in mice

Journal of Virology

Volumn 77, Issue 17, 2003, Pages 9312-9323

  Fischer, Timo ^a   Planz, Oliver ^a   Stitz, Lothar ^a   Rziha, Hanns Joachim ^a  

^a FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GLYCOPROTEIN; GLYCOPROTEIN GC; GLYCOPROTEIN GD; LIVE VACCINE; PERFORIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DELIVERY SYSTEM; DRUG SAFETY; HERPES VIRUS; HERPES VIRUS INFECTION; HOST; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNIZATION; MOUSE; NONHUMAN; PARAPOXVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROVOCATION TEST; PSEUDORABIES HERPETOVIRUS; SPECIES; SWINE; T LYMPHOCYTE; VIRUS RECOMBINANT; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; GENETIC VECTORS; GENOME, VIRAL; HERPESVIRUS 1, SUID; IMMUNITY, CELLULAR; IMMUNIZATION, PASSIVE; IMMUNOLOGIC DEFICIENCY SYNDROMES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; PARAPOXVIRUS; PSEUDORABIES; RECOMBINATION, GENETIC; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 0041387459     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.17.9312-9323.2003     Document Type: Article

References (61)

1. Ben Porat, T., J. M. DeMarchi, B. Lomniczi, and A. S. Kaplan. 1986. Role of glycoproteins of pseudorabies virus in eliciting neutralizing antibodies. Virology 154:325-334.
2. + cells in protective immunity. Vaccine 16:1550-1558.
3. Brenner, G. J., N. Cohen, and J. A. Moynihan. 1994. Similar immune response to nonlethal infection with herpes simplex virus-1 in sensitive (BALB/c) and resistant (C57BL/6) strains of mice. Cell. Immunol. 157:510-524.
4. Büttner, M., and H. J. Rziha. 2002. Parapoxviruses: from the lesion to the viral genome. J. Vet. Med. B Infect. Dis. Vet. Public Health 49:7-16.
5. Cooney, E. L., A. C. Collier, P. D. Greenberg, R. W. Coombs, J. Zarling, D. E. Arditti, M. C. Hoffman, S. L. Hu, and L. Corey. 1991. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 337:567-572.
6. Cottone, R., M. Büttner, B. Bauer, M. Henkel, E. Hettich, and H. J. Rziha. 1998. Analysis of genomic rearrangement and subsequent gene deletion of the attenuated Orf virus strain D1701. Virus Res. 56:53-67.
7. Czerny, C.-P., R. Waldmann, and T. Scheubeck. 1997. Identification of three distinct antigenic sites in parapoxviruses. Arch. Virol. 142:807-821.
8. Drexler, I., K. Heller, B. Wahren, V. Erfle, and G. Sutter. 1998. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 79:347-352.
9. Eloit, M., D. Fargeaud, R. L'Haridon, and B. Toma. 1988. Identification of the pseudorabies virus glycoprotein gp50 as a major target of neutralizing antibodies. Arch. Virol. 99:45-56.
10. Enquist, L. W., P. J. Husak, B. W. Banfield, and G. A. Smith. 1998. Infection and spread of alphaherpesviruses in the nervous system. Adv. Virus Res. 51:237-347.
11. Fachinger, V., T. Schlapp, W. Strube, N. Schmeer, and A. Saalmuller. 2000. Poxvirus-induced immunostimulating effects on porcine leukocytes. J. Virol. 74:7943-7951.
12. Gerdts, V., A. Jons, and T. C. Mettenleiter. 1999. Potency of an experimental DNA vaccine against Aujeszky's disease in pigs. Vet. Microbiol. 66:1-13.
13. Haig, D. M., C. J. McInnes, D. L. Deane, H. W. Reid, and A. A. Mercer. 1997. The immune and inflammatory response to Orf virus. Comp. Immunol. Microbiol. Infect. Dis. 20:197-204.
14. Haig, D. M., and A. A. Mercer. 1998. Ovine diseases: Orf. Vet. Res. 29:311-326.
15. + T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice. J. Gen. Virol. 82:845-853.
16. Ho, T. Y., C. Y. Hsiang, C. H. Hsiang, and T. J. Chang. 1998. DNA vaccination induces a long-term antibody response and protective immunity against pseudorabies virus in mice. Arch. Virol. 143:115-125.
17. Hong, W., S. Xiao, R. Zhou, L. Fang, Q. He, B. Wu, F. Zhou, and H. Chen. 2002. Protection induced by intramuscular immunization with DNA vaccines of pseudorabies in mice, rabbits and piglets. Vaccine 20:1205-1214.
18. Hussain, K. A., and D. Burger. 1989. In vivo and in vitro characteristics of contagious ecthyma virus isolates: host response mechanism. Vet. Microbiol. 19:23-36.
19. Inoshima, Y., A. Morooka, K. Murakami, and H. Sentsui. 2000. Simple preparation of parapoxvirus genome DNA for endonuclease analysis. Microbiol. Immunol, 44:69-72.
20. + T lymphocytes. Nature 421:852-856.
21. Kagi, D., and H. Hengartner. 1996. Different roles for cytotoxic T cells in the control of infections with cytopathic versus noncytopathic viruses. Curr. Opin. Immunol. 8:472-477.
22. Karupiah, G., Q. W. Xie, R. M. Buller, C. Nathan, C. Duarte, and J. D. MacMicking. 1993. Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science 261:1445-1448.
23. Kundig, T. M., C. P. Kalberer, H. Hengartner, and R. M. Zinkernagel. 1993. Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine 11:1154-1158.
24. + T-cells and a humoral immune response are important for the elimination of Orf virus from the skin of sheep. Vet. Immunol. Immunopathol. 74:249-262.
25. MacLean, A., X. Q. Wei, F. P. Huang, U. A. Al Alem, W. L. Chan, and F. Y. Liew. 1998. Mice lacking inducible nitric-oxide synthase are more susceptible to herpes simplex virus infection despite enhanced Th1 cell responses. J. Gen. Virol. 79:825-830.
26. + T lymphocytes. J. Immunol. 155:259-265.
27. Marchioli, C., R. J. Yancey, Jr., J. G. Timmins, L. E. Post, B. R. Young, and D. A. Povendo. 1988. Protection of mice and swine from pseudorabies virus-induced mortality by administration of pseudorabies virus-specific mouse monoclonal antibodies. Am. J. Vet. Res. 49:860-864.
28. Martin, R. M., J. L. Brady, and A. M. Lew. 1998. The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J. Immunol. Methods 212:187-192.
29. Matsuda, T. A., S. Katayama, N. Okada, T. Okabe, and N. Sasaki. 1992. Protection from pseudorabies virus challenge in mice by a combination of purified gII, gIII and gVI antigens. J. Vet. Med. Sci. 54:447-452.
30. Mayr, A. 2001. Altered strain of the modified vaccinia virus Ankara (MVA). WO 01/68820 A1. World Intellectual Property Organization, Geneva, Switzerland.
31. Mayr, A., M. Herlyn, H. Mahnel, A. Danco, A. Zach, and H. Bostedt. 1981. Control of contagious ecthyma in sheep by means of a new parenteral cell culture derived live vaccine. J. Med. Vet. B 28:535-549.
32. Mengeling, W. L., S. L. Brockmeier, and K. M. Lager. 1994. Evaluation of a recombinant vaccinia virus containing pseudorabies (PR) virus glycoprotein genes gp50, gII, and gIII as a PR vaccine for pigs. Arch. Virol. 134:259-269.
33. Mettenleiter, T. C. 1996. Immunobiology of pseudorabies (Aujeszky's disease). Vet. Immunol. Immunopathol. 54:221-229.
34. Meyer, M., M. Clauss, A. Lepple-Wienhues, J. Waltenberger, H. G. Angustin, M. Ziche, C. Lanz, M. Büttner, H. J. Rziha, and C. Dehio. 1999. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J. 18:363-374.
35. Morgado. M. G., P. Cam, C. Gris-Liebe, P. A. Cazenave, and E. Jouvin-Marche. 1989. Further evidence that BALB/c and C57BL/6 gamma 2a genes originate from two distinct isotypes. EMBO J. 8:3245-3251.
36. Morrison, L. A., L. Zhu, and L. G. Thebeau. 2001. Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells. J. Virol. 75:1195-1204,
37. Moss, B. 1996. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. USA 93:11341-11348.
38. Moss, B., M. W. Carroll, L. S. Wyatt, J. R. Bennink, V. M. Hirsch, S. Goldstein, W. R. Elkins, T. R. Fuerst, J. D. Lifson, M. Piatak, N. P. Restifo, W. Overwijk, R. Chamberlain, S. A. Rosenberg, and G. Sutter. 1996. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv. Exp. Med. Biol. 397:7-13.
39. Ober, B. T., P. Bruhl, M. Schmidt, V. Wieser, W. Gritschenberger, S. Coulibaly, H. Savidis-Dacho, M. Gerencer, and F. G. Falkner. 2002. Immunogenicity and safety of defective vaccinia virus Lister: comparison with modified vaccinia virus Ankara. J. Virol. 76:7713-7723.
40. Ober, B. T., B. Teufel, K.-H. Wiesmüller, G. Jung, E. Pfaff, A. Saalmüller, and H. J. Rziha. 2000. The porcine humoral immune response against pseudorabies virus specifically targets attachment sites on glycoprotein gC. J. Virol. 74:1752-1760.
41. Paoletti, E. 1996, Applications of pox virus vectors to vaccination: an update. Proc. Natl. Acad. Sci. USA 93:11349-11353.
42. Paoletti, E., J. Taylor, B. Meignier, C. Meric, and J. Tartaglia 1995. Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC. Dev. Biol. Stand. 84:159-163.
43. Perkus, M. E., A. Piccini, B. R. Lipinskas, and E. Paoletti. 1985. Recombinant vaccinia virus: immunization against multiple pathogens. Science 229:981-984.
44. Rahemtulla, A., T. M. Kundig, A. Narendran, M. F. Bachmann, M. Julius, C. J. Paige, P. S. Ohashi, R. M. Zinkernagel, and T. W. Mak. 1994. Class II major histocompatibility complex-restricted T cell function in CD4-deficient mice. Eur. J. Immunol. 24:2213-2218.
45. Ramirez, J. C., G. M. Gerhardi, and M. Esteban. 2000. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J. Virol. 74:923-933.
46. Riviere, M., J. Tartaglia, M. E. Perkus, E. K. Norton, C. M. Bongermino, F. Lacoste, C. Duret, P. Desmettre, and E. Paoletti. 1992. Protection of mice and swine from pseudorabies virus conferred by vaccinia virus-based recombinants. J. Virol. 66:3424-3434.
47. Robinson, A. J. and D. J. Lyttle. 1992. Parapoxviruses: their biology and potential as recombinant vaccines, p. 285-327. In M. M. Binns and G. L. Smith (ed.), Recombinant poxviruses. CRC Press, Inc., Boca Raton, Fla.
48. Rooney, J. F., C. Wohlenberg, K. J. Cremer, B. Moss, and A. L. Notkins. 1988. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination. J. Virol. 62:1530-1534.
49. Rziha, H.-J., B. Bauer, K.-H. Adam, M. Röttgen, R. Cottone, M. Henkel, C. Dehio, and M. Büttner. 2003. Relatedness and heterogeneity at the near-terminal end of the genome of parapoxvirus bovis 1 strain (B177) compared with parapoxvirus ovis (Orf virus). J. Gen. Virol. 84:1111-1116.
50. Rziha, H. J., M. Henkel, R. Cottone, B. Bauer, U. Auge, F. Götz, E. Pfaff, M. Röttgen, C. Dehio, and M. Büttner. 2000. Generation of recombinant parapoxviruses: non-essential genes suitable for insertion and expression of foreign genes. J. Biotechnol. 83:137-145.
51. Savory, L. J., S. A. Stacker, S. B. Fleming, B. E. Niven, and A. A. Mercer. 2000. Viral vascular endothelial growth factor plays a critical role in Orf virus infection. J. Virol. 74:10699-10706.
52. Schijns, V. E., B. L. Haagmans, and M. C. Horzinek. 1995. IL-12 stimulates an antiviral type 1 cytokine response but lacks adjuvant activity in IFN-gamma-receptor-deficient mice. J. Immunol. 155:2525-2532.
53. Schijns, V. E., B. L. Haagmans, E. O. Rijke, S. Huang, M. Aguet, and M. C. Horzinek. 1994. IFN-gamma receptor-deficient mice generate antiviral Th1-characteristic cytokine profiles but altered antibody responses. J. Immunol. 153:2029-2037.
54. + T-cell-independent immunoglobulin responses by inactivated influenza virus. J. Virol. 74:4999-5005.
55. Sharpe, S., N. Polyanskaya, M. Dennis, G. Sutter, T. Hanke, V. Erfle, V. Hirsch, and M. Cranage. 2001. Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity. J. Gen. Virol. 82:2215-2223.
56. + T cell-mediated protective immunity against herpes simplex virus type 2 in vivo. Hum. Gene Ther. 12:1091-1102.
57. Snapper, C. M., and W. E. Paul. 1987. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236:944-947.
58. Wittmann, G., and H.-J. Rziha. 1989. Aujeszky's disease (pseudorabies) in pigs, p. 230-325. In G. Wittmann (ed.), Herpesvirus diseases of cattle, horses, and pigs. Kluwer Academic, Boston, Mass.
59. Zarnke, R. L., and R. A. Dieterich. 1985. Attempted reactivation of contagious ecthyma in Dall sheep. Am. J. Vet. Res. 46:1775-1776.
60. Zinkernagel, R. M. 1996. Immunology taught by viruses. Science 271:173-178.
61. Zuckermann, F. A., L. Zsak, T. C. Mettenleiter, and T. Ben-Porat. 1990. Pseudorabies virus glycoprotein gIII is a major target antigen for murine and swine virus-specific cytotoxic T lymphocytes. J. Virol. 64:802-812.